Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


August 31, 2015 1:23 AM ET

Pharmaceuticals

Company Overview of Novartis Institutes for BioMedical Research, Inc.

Company Overview

Novartis Institutes for BioMedical Research, Inc. operates as a pharmaceutical research organization. The company was incorporated in 2002 and is based in Cambridge, Massachusetts. Novartis Institutes for BioMedical Research, Inc. operates as a subsidiary of Novartis AG.

250 Massachusetts Avenue

Cambridge, MA 02139

United States

Founded in 2002

Phone:

617-871-8000

Fax:

617-551-9540

Key Executives for Novartis Institutes for BioMedical Research, Inc.

President
Age: 64
Head of Public Relations
Deputy Chief Financial Officer and Chief Financial Officer of Novartis AG
Age: 56
Chief Operating Officer
Age: 59
Chief Executive Officer of Novartis Animal Health
Age: 64
Compensation as of Fiscal Year 2015.

Novartis Institutes for BioMedical Research, Inc. Key Developments

Novartis Institutes for Biomedical Research, Inc. Initiates Phase I of PCA062

On May 20, 2015, Novartis Institutes for BioMedical Research, Inc. notified ImmunoGen, Inc. that it had initiated Phase I, first-in-human clinical testing of a product candidate, PCA062, utilizing antibody-drug conjugate technology. Pursuant to the license taken under 2010 Multi-Target Agreement, this start of clinical testing triggers a $5 million milestone payment to ImmunoGen.

Novartis Institutes for BioMedical Research, Inc. Presents at 8th Annual EUROPEAN LIFE SCIENCE CEO FORUM & EXHIBITION, Mar-03-2015 12:15 PM

Novartis Institutes for BioMedical Research, Inc. Presents at 8th Annual EUROPEAN LIFE SCIENCE CEO FORUM & EXHIBITION, Mar-03-2015 12:15 PM. Venue: Hilton, Zurich Airport Hotel, Hohenbuehlstrasse 10, Opfikon-Glattbrugg 8152 Zurich, Zurich, Switzerland. Speakers: Rao Movva, Executive Director.

SomaLogic, Inc. Announces Extension of Multi-Year Collaboration Agreement with Novartis Institutes for BioMedical Research

SomaLogic, Inc. announced that Novartis has extended its multi-year research agreement for the development and application of SomaLogic's unique proteomics technology to Novartis' drug discovery and development efforts. Novartis will also take an equity position in SomaLogic under the agreement extension. Under the previous collaboration agreement, scientists at the Novartis Institutes for BioMedical Research and SomaLogic worked together to build an enhanced proprietary version of SomaLogic's SOMAscan proteomics assay for NIBR. The collaboration also included development of specific novel SOMAmer binding reagents for multiple preclinical and clinical applications in NIBR's research and development portfolio. The collaboration extension announced will enhance and expand these efforts in addition to the equity investment in SomaLogic. Other specific terms of the agreement were not disclosed. Compared to other current proteomic technologies, SomaLogic's offerings provide researchers with unprecedented power for protein biomarker discovery, diagnostics development, and pharmaceutical discovery and development. SOMAmer reagents, which are at the center of SomaLogic's proteomics platform, are a new class of superior protein-binding reagents that combine the best properties of both monoclonal antibodies and traditional aptamers. They have wide applicability in many current preclinical and clinical analytical assays, including quantitative high-content screening, targeted panels, flow cytometry, histochemistry, functional assays, and biophysical methods. SomaLogic's commercially available SOMAscan assay, which incorporates 1,129 different SOMAmer reagents, can efficiently, accurately, and rapidly measure proteins across a wide range of concentrations in small volumes of multiple biological sample types.

Similar Private Companies By Industry

Company Name Region
RP Select Finance Trust United States
Pedinol Pharmacal, Inc. United States
Alitair Pharmaceuticals, Inc. United States
Plantaceutica, Inc United States
UPM Pharmaceuticals, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
April 15, 2015
Aduro BioTech, Inc.
Merger/Acquisition
March 5, 2015
Novartis Institutes for BioMedical Research, Inc., RNAi Assets
Private Placement
January 8, 2015
Surface Oncology, Inc.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Novartis Institutes for BioMedical Research, Inc., please visit www.nibr.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.